Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis

Frontiers in Bioengineering and Biotechnology
Qiang ZhangFang Cao

Abstract

Immune checkpoints target regulatory pathways in T cells that enhance antitumor immune responses and elicit durable clinical responses. As a novel immune checkpoint, CD96 is an attractive key target for cancer immunotherapy. However, there has been no integrative investigation of CD96 in glioma. Our study explored the relationship between CD96 expression and clinical prognosis in glioma. RNA and clinical data for a total of 1,001 samples were included in this study, including 325 samples from the Chinese Glioma Genome Atlas (CGGA) database and 676 samples from The Cancer Genome Atlas (TCGA) dataset. The R programming language was employed to perform statistical analysis and draw figures. CD96 had a consistently positive relationship with glioblastoma and was highly enriched in IDH-wildtype and mesenchymal subtype glioma. Gene ontology enrichment and gene set variation analysis analyses suggested that CD96 was mostly involved in immune functions and was especially related to T cell-mediated immune response in glioma. Subsequent immune infiltration analysis showed that CD96 was positively correlated with infiltrating levels of CD4 + T and CD8 + T cells, macrophages, neutrophils, and DCs in glioblastoma multiforme and low-grade gl...Continue Reading

References

Mar 23, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anja FuchsMarco Colonna
May 7, 2010·CA: a Cancer Journal for Clinicians·Erwin G Van MeirJeffrey J Olson
Mar 19, 2011·BMC Bioinformatics·Xavier RobinMarkus Müller
Mar 30, 2012·Omics : a Journal of Integrative Biology·Guangchuang YuQing-Yu He
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jan 18, 2013·BMC Bioinformatics·Sonja HänzelmannJustin Guinney
Sep 6, 2014·Neuro-oncology·David A ReardonGlenn Dranoff
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Mar 12, 2016·Cancer Letters·Tao JiangUNKNOWN Chinese Glioma Cooperative Group (CGCG)
Mar 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric BouffetUri Tabori
Mar 5, 2017·Immunological Reviews·William C DougallAna C Anderson
May 26, 2017·Frontiers in Pharmacology·Jing HuangJindong Chen
Nov 11, 2017·Neuro-oncology·Francesca BranzoliMalgorzata Marjanska
Jan 11, 2018·The New England Journal of Medicine·Michael A PostowMatthew D Hellmann
Mar 24, 2018·Science·Antoni Ribas, Jedd D Wolchok
Jun 6, 2018·Frontiers in Immunology·Hristo GeorgievGünter Bernhardt
Nov 10, 2018·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Haoyu SunCheng Sun
Mar 22, 2019·Cancer Immunology Research·Deepak MittalMark J Smyth

❮ Previous
Next ❯

Citations

Jul 27, 2021·Frontiers in Immunology·Amina GhouzlaniAbdallah Badou

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-seq

Software Mentioned

RSEM
survival
AmiGO
survminer
R packages
TIMER
corrgram
R
R package ‘ clusterProfiler ’
GSVA

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.